The drug, approved by the FDA last week, is approved to treat osteoporosis in postmenopausal women at high risk of bone fracture. The drug carries a boxed warning, which flags increased risk of heart attack, stroke and cardiovascular-related deaths.
Evenity, part of a new class of drugs known as sclerostin inhibitors, is designed to reduce the risk of fracture by building bone mass and inhibiting the breakdown of bone minerals.
Analysts expect Evenity to pull in revenue of $274 million by 2024.
More articles on pharmacy:
PBM hearing should prompt bill to ban ‘secrecy’ in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy
